leadf
logo-loader
viewRevive Therapeutics

Revive Therapeutics set to collaborate with University of Wisconsin System on Psilocybin clinical trial

The trial is for the potential treatment of methamphetamine use disorder

Revive Therapeutics -
The clinical study, in collaboration with the university, is entitled: "Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder."

Revive Therapeutics Ltd (CSE:RVV) (OTCMKTS:RVVTF) said it has stuck a clinical trial agreement (CTA) with the University of Wisconsin System (UWS) to advance its psilocybin therapy for the potential treatment of methamphetamine use disorder.

The disorder is caused by the recurrent use of the substance methamphetamine and causes various problems including physical withdrawal, increasing use, and failure to meet responsibilities at work or school.

READ: Revive Therapeutics wins Institutional Review Board approval for its Phase 3 trial protocol to evaluate Bucillamine in COVID-19 patients

Life sciences group Revive is developing its oral dosage forms of psilocybin -  the chemical found in magic mushrooms - to treat a variety of diseases and disorders.

"We are delighted to be collaborating with clinical researchers at the University of Wisconsin‒Madison to advance development of psilocybin for the potential treatment of methamphetamine use disorder,” said Michael Frank, Revive’s CEO in a statement.

"We are building a pipeline of clinical-stage psychedelic-derived therapies for addiction disorders with a focus on psilocybin with unique dosage forms."

The clinical study, in collaboration with the university, is entitled: "Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder."

Under the terms of the agreement, Revive has an exclusive option to obtain an exclusive, worldwide, royalty-bearing commercialization license to all rights, title and interest that UWS may have in any invention that results from the clinical study.

Contact the author at [email protected]

Quick facts: Revive Therapeutics

Price: 0.225 CAD

CSE:RVV
Market: CSE
Market Cap: $36.89 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Revive Therapeutics named herein, including the promotion by the Company of Revive Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Revive Therapeutics: Analyst sees 'substantial upside potential' as key...

Proactive Research analyst Ed Stacey says Revive Therapeutics (CSE:RVV)(OTCQB:RVVTF) is a speciality life sciences company focussed on repurposing drugs for rare and infectious diseases and has a pipeline of of three main platforms. One of them is Bucillamine (BUC) which is a medication with a...

on 06/30/2020

2 min read